Moleculin Biotech (MBRX) has issued an announcement.
Moleculin Biotech, Inc. announced that their drug Annamycin received Orphan Drug Designation from the European Medicines Agency for treating Acute Myeloid Leukemia (AML). This designation is a positive development for the company, signaling potential market exclusivity and benefits that could interest investors monitoring biotech sector advancements.
Learn more about MBRX stock on TipRanks’ Stock Analysis page.
